Abstracts Archive - Page 396 of 2425 - ACR Meeting Abstracts

Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass¹, Noha Abdel-Wahab², Pankti Reid³, Jeffrey Sparks⁴, Cassandra Calabrese⁵, Deanna Jannat-Khah, DrPH, MSPH⁶, Diviya Rajesh⁶, Nilasha Ghosh⁶, Komal Mushtaq⁷, Farah Al Haj⁸, Adewunmi Falohun⁹, Lydia Gedmintas¹⁰, Lindsey MacFarlane¹¹, Senada Arabelovic¹¹, Adi Diab², Ami Shah¹², Clifton O. Bingham III¹³, Karmela Kim Chan⁶ and Laura C. Cappelli¹⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²UT MD Anderson Cancer Center, Houston, TX, ³University of Chicago Medical Center, Chicago, IL, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH, ⁶Hospital for Special Surgery, New York, NY, ⁷Cleveland Clinic, Cleveland, OH, ⁸Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, ⁹MD Anderson Cancer Center, Houston, TX, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
Abstract Number: 1667 • ACR Convergence 2022
Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibitors for Cancer Treatment: A Comparative Cohort Study Investigating RA Flare and Mortality
Kaitlin McCarter¹, Taylor Wolfgang¹, Senada Arabelovic¹, Xiaosong Wang¹, Kazuki Yoshida¹, Emily Banasiak¹, Grace Qian¹, Emily Kowalski¹, Kathleen Vanni¹, Nicole LeBoeuf¹, Elizabeth Buchbinder¹, Lydia Gedmintas¹, Lindsey MacFarlane¹, Deepak Rao¹, Nancy Shadick¹, Ellen Gravallese² and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: For patients with pre-existing RA, immune checkpoint inhibitors (ICIs) for cancer treatment may trigger RA flares or other immune-related adverse events. Underlying altered immunity…
Abstract Number: 1536 • ACR Convergence 2022
Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR
Anna-Maria Hoffmann-Vold¹, Cathrine Brunborg¹, Paolo Airò², Lidia P. Ananyeva³, László Czirják⁴, Serena Guiducci⁵, Eric Hachulla⁶, MENGTAO LI⁷, Carina Mihai⁸, Gabriela Riemekasten⁹, Petros P. Sfikakis¹⁰, Gabriele Valentini¹¹, Otylia Kowal-Bielecka¹², Yannick Allanore¹³ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ³V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁴Medical school of Pécs, Pecs, Hungary, ⁵University of Firenze, Firenze, Italy, ⁶University of Lille, Lille, France, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁹University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁰Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ¹¹Università della Campania “Luigi Vanvitelli”, Napoli, Italy, ¹²Medical University of Bialystok, Bialystok, Poland, ¹³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: Short disease duration is a well known predictor for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD), but studies assessing ILD progression in later disease…
Abstract Number: 1673 • ACR Convergence 2022
Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort
SABRINA HAMROUN¹, Marion Couderc², Rene-Marc Flipo³, Jérémie SELLAM⁴, Christophe Richez⁵, Emmanuelle Dernis⁶, Aline Frazier-Mironer⁷, Laure Gossec⁸, elisabeth gervais⁹, Hubert Marotte¹⁰, Laetitia Dunogeant¹¹, Cédric Lukas¹², Alban DEROUX¹³, Nathalie Costedoat-Chalumeau¹⁴ and Anna Molto¹⁵, ¹Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, ²University Hospital, Clermont-Ferrand, France, ³CHU Lille, Boulogne-Billancourt, France, ⁴Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶LE MANS general hospital, LE MANS, France, ⁷APHP Hôpital Lariboisire, Paris, France, ⁸Sorbonne Université, Paris, France, ⁹chu poitiers, Poitiers, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹Hospital of Aix en Provence, Marseille, France, ¹²University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ¹³CHU Grenoble, Grenoble, France, ¹⁴Inserm DR Paris 5, Paris, France, ¹⁵Rheumatology Department, Cochin Hospital, APHP, Paris, France
Background/Purpose: Spondyloarthritis (SpA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge about…
Abstract Number: 1672 • ACR Convergence 2022
The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire
Maria Grazia Lazzaroni¹, Liala Moschetti¹, Eleonora Pedretti¹, Andrea Lojacono², Francesca Ramazzotto³, Cristina Zanardini³, Zatti Sonia³, Angela Tincani⁴, Franco Franceschini¹, Paolo Airò⁵ and Laura Andreoli¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Obstetrics and Gynecology, ASST Garda, Desenzano del Garda, Brescia, Brescia, Italy, ³Obstetrics and Gynecology, ASST Spedali Civili and University of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, ⁵Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy
Background/Purpose: Systemic Sclerosis (SSc) has a strong female predominance and can significantly impair the everyday quality of life of patients. We aimed at designing a…
Abstract Number: 1660 • ACR Convergence 2022
Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality
Julie Paik¹, Caoilfhionn Connolly¹, Fredrick Wigley¹ and Laura Hummers², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Univerisity, Baltimore, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is poorly understood. The etiology of myopathy in SSc is heterogeneous and can result from an inflammation, disuse,…
Abstract Number: 1633 • ACR Convergence 2022
Genetic Risk, Adherence to a Healthy Lifestyle, and Incident Gout in US Women and Men
Kehuan Lin¹, Natalie McCormick¹, Leo Lu², amit johi³, Chio Yokose⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Regeneron, Boston, MA, ⁴Massachusetts General Hospital, Waltham, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Lifestyle and genetic factors have been independently related to incident gout risk. However, it remains unknown whether the genetic risk of gout is affected…
Abstract Number: 1601 • ACR Convergence 2022
Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial
Michaela Koehm¹, Ann Christina Foldenauer², Tanja Rossmanith³, Herbert Kellner⁴, Uta Kiltz⁵, Juergen Rech⁶, Gerd Burmester⁷, David Kofler⁸, Jan Brandt-Juergens⁹, Stephanie Finzel¹⁰, Raoul Bergner¹¹, Maren Sieburg¹² and Frank Behrens¹³, ¹Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ³Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, Germany, ⁴Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶University Clinic Erlangen, Erlangen, Germany, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ¹⁰University of Freiburg, Freiburg, Germany, ¹¹Klinikum Ludwigshafen, Ludwigshafen, Germany, ¹²Rheumatologische Facharztpraxis, Magdeburg, Germany, ¹³Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany
Background/Purpose: Subgroup analysis from different clinical trials and real-world data suggest, that there are differences in baseline characteristics, clinical phenotypes, and treatment responses in female…
Abstract Number: 1610 • ACR Convergence 2022
Are Serological Protease-mediated Peptides of Tissue Remodeling and Inflammation the New Disease Activity Biomarkers in Psoriatic Arthritis Patients?
Solveig S. Groen¹, Signe Holm Nielsen², Anne-Christine Bay-Jensen², Mozhgan Rasti³, Darshini Ganatra³, Katerina Oikonomopoulou³ and Vinod Chandran⁴, ¹Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Inflammatory and degenerative processes in the joint tissues are hallmarks of patients with psoriatic arthritis (PsA). Here, proteases play a major role in remodeling…
Abstract Number: 1644 • ACR Convergence 2022
Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Metabolic Syndrome-Associated Osteoarthritis: A Randomized Controlled Trial
Wendy Walrabenstein¹, Carlijn Wagenaar¹, Marike van der Leeden², Martijn Gerritsen¹, Martin van der Esch¹ and Dirkjan van Schaardenburg², ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: Metabolic syndrome with low grade inflammation is associated with chronic diseases including osteoarthritis (OA) (1). A combination of an intensive diet with exercise produced…
Abstract Number: 1405 • ACR Convergence 2022
In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker
Patryk Drobinski¹, Neel I. Nissen¹, morten A. Karsdal², Nicholas Willumsen² and Anne-Christine Bay-Jensen², ¹University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: The degree of protein citrullination and degradation by matrix metalloproteinases (MMP) play a central role in the pathology of rheumatoid arthritis (RA). Autoantibodies are…
Abstract Number: 1671 • ACR Convergence 2022
Current Cervical Cancer Screening Guidelines Are Unsatisfactory for the Needs of Systemic Lupus Erythematosus Patients
Zehra Kazmi¹, Carlos Lorenzo¹, Farwa Kazmi² and Agustin Escalante³, ¹University of Texas Health Sciences Center San Antonio, San antonio, TX, ²Gulf Medical University, Ajman, United Arab Emirates, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: HPV infection is a risk factor for cervical cancer. SLE patients have increased rates of HPV infection, cervical dysplasia and cancer. Present guidelines for…
Abstract Number: 1652 • ACR Convergence 2022
Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
Kenneth C. Kalunian¹, Richard A. Furie², Eric F. Morand³, Ian N. Bruce⁴, Susan Manzi⁵, Yoshiya Tanaka⁶, Kevin Winthrop⁷, Gabriel Abreu⁸, Ihor Hupka⁹, Lijin Zhang¹⁰, Shanti Werther¹¹, Micki Hultquist¹², Raj Tummala¹⁰ and Catharina Lindholm¹¹, ¹UC San Diego, La Jolla, CA, ²Northwell Health, Great Neck, NY, ³Monash University, Melbourne, Australia, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Oregon Health & Science University, Portland, OR, ⁸AstraZeneca, Mölndal, Sweden, ⁹AstraZeneca, Warsaw, Poland, ¹⁰AstraZeneca, Gaithersburg, MD, ¹¹AstraZeneca, Gothenburg, Sweden, ¹²AstraZeneca, Bethesda, MD
Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody that binds to the type I IFN receptor and inhibits type I IFN signaling.1 In…
Abstract Number: 1621 • ACR Convergence 2022
Genome-wide Association Study in African American Systemic Sclerosis Patients Identifies a Novel Target – Transforming Growth Factor-β3 (TGFβ3)
Urvashi Kaundal¹, Julia Hartman², Emilee Stenson¹, Sarah Safran¹, Chloe Borden¹, Mousumi Sahu¹, Janet Wang¹, Andrea Conte¹, Ami Shah³, Maureen Mayes⁴, Ayo Doumatey⁵, Amy Bentley⁵, Daniel Shriner⁵, Robyn Domsic⁶, Thomas Medsger⁷, Paula Ramos⁸, Richard Silver⁸, Virginia Steen⁹, John Varga¹⁰, Vivien Hsu¹¹, Lesley Ann Saketkoo¹², Elena Schiopu¹³, Dinesh Khanna¹⁴, Jessica Gordon¹⁵, Lindsey Criswell¹⁶, Heather Gladue¹⁷, Chris Derk¹⁸, Elana Bernstein¹⁹, S. Louis Bridges, Jr.¹⁵, Victoria Shanmugam²⁰, Lorinda Chung²¹, Suzanne Kafaja²², Reem Jan²³, Marcin Trojanowski²⁴, Avram Goldberg²⁵, Benjamin Korman²⁶, Settara Chandrasekharappa⁵, Yongbing Zhao²⁷, Stephen Brooks²⁷, Stefania Dell'Orso¹, Adebowale Adeyemo⁵, Charles Rotimi⁵, Elaine Remmers⁵, Daniel Kastner⁵, Francesco Boin²⁸, Rafael Casellas²⁷, Fredrick Wigley²⁹ and Pravitt Gourh³⁰, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁵National Human Genome Research Institute, Bethesda, MD, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁸Medical University of South Carolina, Charleston, SC, ⁹Georgetown University School of Medicine, Washington, DC, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Rutgers-RWJ Medical School, South Plainfield, NJ, ¹²University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹³Michigan Medicine, Ann Arbor, MI, ¹⁴Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶National Human Genome Research Institute, NIH, Bethesda, MD, ¹⁷Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Columbia University, New York, NY, ²⁰George Washington University, Great Falls, VA, ²¹Stanford University, Stanford, CA, ²²UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, ²³University of Chicago, Chicago, IL, ²⁴Boston University School of Medicine, Boston, MA, ²⁵NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁶University of Rochester, Rochester, NY, ²⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²⁸Cedars-Sinai Medical Center, Los Angeles, CA, ²⁹Johns Hopkins University, Baltimore, MD, ³⁰National Institutes of Health, Bethesda, MD
Background/Purpose: Transforming Growth Factor-β (TGFβ) isoforms play an important role in extracellular matrix biology. Increased TGFβ-regulated gene signature has been observed in lesional skin and…
Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Alba Herrero-Morant¹, José Luis Martín-Varillas², Santos Castañeda³, Olga Maiz⁴, Julio Sánchez-Martín⁵, Norberto Ortego⁶, Enrique Raya⁷, Águeda Prior-Español⁸, Clara Moriano⁹, Rafael Melero¹⁰, Genaro Graña-Gil¹¹, Ana Urruticoechea¹², Angel Ramos¹³, Marta Loredo-Martínez¹⁴, Eva Salgado-Pérez¹⁵, Francisca Sivera¹⁶, Ignacio Torre¹⁷, F. Javier Narváez¹⁸, Jose Luis Andreu¹⁹, Olga Martinez²⁰, Ricardo Gómez-de la Torre²¹, Sabela Fernandez-Aguado²², Susana Romero Yuste²³, iñigo Gonzalez-Mazon⁵, Carmen Alvarez Reguera⁵, David Martínez-López⁵, José Luis Hernández⁵, Miguel Ángel González-Gay²⁴ and Ricardo Blanco²⁵, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital de Laredo, Laredo, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Hospital Universitario de Donostia, San Sebastián, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Medicine Department, Universidad de Granada, Granada, Spain, ⁷Hospital San Cecilio, Granada, Spain, ⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁹Complejo Asistencial Universitario de León, León, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Hospital Universitario de A Coruña, A Coruña, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Complejo Hospitalario de Soria, Soria, Spain, ¹⁴Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ¹⁶Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁷Hospital de Basurto, Basurto, Spain, ¹⁸Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²²Hospital Universitario de Cabueñes, Gijon, Spain, ²³Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].